
Enzo Biochem, Inc.
- Jurisdiction
United States - LEI
5299001N23WBO4XQ2P60 - ISIN
US2941001024 (ENZ )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. Read full profile
Stock price
Fundamentals
- Net revenue
€23.57M - Gross margin
43.8% - EBIT
-€9.20M - EBIT margin
-39.0% - Net income
-€18.09M - Net margin
-76.7%
Statement period: - (published )
Dividends
- Last dividend amount
-
$0.10 - Ex date
-
- Payment date
-
Earnings Calls
Latest earnings call: December 13, 2022
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |